Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Iowa › Cedar Rapids
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Cedar Rapids, IA
12 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi sekitar Cedar Rapids (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Menerima pesertaFase 3
- Saint Luke's Hospital, Cedar Rapids
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Menerima pesertaFase 2/3
- Site#0140, Iowa City · 25 mi jauhnya
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- University of Iowa Hospital and Clinics, Iowa City · 25 mi jauhnya
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Menerima pesertaFase 2/3
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauhnya
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- University of Iowa, Iowa City · 25 mi jauhnya
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauhnya
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Menerima pesertaFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- University of Iowa, Iowa City · 25 mi jauhnya
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- University of Iowa, Iowa City · 25 mi jauhnya
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 3
- GSK Investigational Site, Iowa City · 25 mi jauhnya
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di kota lain
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- New York City, NY39 studi
- Nashville, TN39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Chicago, IL26 studi
- Philadelphia, PA26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- Pittsburgh, PA22 studi
Studi lain di Cedar Rapids
- Kanker Paru Non-Sel Kecil20 studi
- Kanker Payudara17 studi
- Kanker (semua jenis)16 studi
- Leukemia Mieloid Akut16 studi
- Mieloma Multipel15 studi
- Kanker Paru14 studi
- Kanker Kolorektal13 studi
- Kanker Prostat12 studi
- Stroke10 studi
- Melanoma10 studi
- Kanker Endometrium9 studi
- Kanker Darah9 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.